INC Research Strengthens Asia/Pacific Capabilities Through Two New Offices in Japan

Offices in Osaka and Shinagawa in Tokyo provide strong clinical development hub for customers in world's second largest pharmaceutical market

Raleigh, NC – INC Research LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced the establishment of INC Research Japan KK with the opening of new locations in Osaka and the Shinagawa ward in Tokyo. The new operations provide INC Research's global drug development customers access to an increasingly significant market and further expand the Company's presence in the Asia/Pacific region. INC Research now has 20 offices in key locations across the Asia/Pacific region in addition to Japan, including a presence in China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand, Indonesia and New Zealand.

"There is a growing enthusiasm from both pharma and government sectors for Japan to be involved in both global and regional clinical trials," said Garth Tierney , Executive Vice President, Asia/Pacific. "In response, INC Research is implementing a very considered approach to the market that will create greater confidence among our customers in conducting trials in Japan, as well as ultimately provide more direct influence on how trials are conducted. Our Japanese customers already have responded positively to our Trusted Process methodology as it fits well with their requirements for high quality and predictability. We are very enthusiastic about bringing the continued benefits of drug development in this country to our customers."

Through INC Research's unique approach to the Japan market, the two offices initially will feature a core group of highly qualified, English-speaking management, regulatory and therapeutic staff who will create a bridge between the Company's Trusted Process methodology and the way clinical research has traditionally been conducted in Japan. The establishment of Japanese business operations builds on INC Research's long-term experience in Japan where it has partnered with local CROs to conduct numerous trials across a variety of therapeutic areas.

The Osaka office is located at Level 19  Hilton Plaza West Office Tower, 2-2-2 UMEDA, Kita-ku, Osaka 530-0001 and the Tokyo office is located at Level 28 Shinagawa Intercity Tower A, 2-15-1 Konan Minato-ku, Tokyo 108-6028. Both locations are strategically placed to serve major drug development areas and are connected by the region's bullet train.

INC Research has provided Phase I to IV clinical development services in the Asia/Pacific region for nearly 20 years , conducting more than a 1,000 studies across a broad range of therapeutic areas. For more information on INC Research's clinical trial services and experience in Japan, please call +81-6-6450 9360 or visit the website.

About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process® methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit or follow us at @inc_research.

Suggested Articles

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.

After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.

The initiative will see Evotec mine a kidney biobank for new renal therapy targets before the joint venture out-licenses resulting assets to Vifor.